Activated clearance of a biotinylated macromolecular MRI contrast agent from the blood pool using an avidin chase

被引：32
作者：
Kobayashi, H [1 ]
Kawamoto, S
Star, RA
Waldmann, TA
Brechbiel, MW
Choyke, PL
机构：
[1] NCI, Metab Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[2] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA
[3] NCI, Radiat Oncol Branch, Radioimmune & Inorgan Chem Sect, NIH, Bethesda, MD 20892 USA
[4] NIDDKD, Renal Diagnost & Therapeut Univ, NIH, Bethesda, MD 20892 USA
[5] Diagnost Radiol Dept, Ctr Clin, NIH, Bethesda, MD 20892 USA
来源：
BIOCONJUGATE CHEMISTRY | 2003年 / 14卷 / 05期
关键词：
D O I：
10.1021/bc034064l
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
The enhancement characteristics of a contrast agent are dependent on its pharmacokinetics within the body. In the case of macromolecular contrast agents, prolonged enhancement of the blood pool is seen after the first dose, limiting opportunities for repeated injection in the same session. If the enhancement within the blood pool could be intentionally switched off, the macromolecular contrast agents could be used both to define blood volume and vessel permeability, properties that could be useful in studying angiogenesis. In the current study, the avidin-biotin system was coupled to a dendrimer-based macromolecular MRI contrast agent to switch enhancement from the blood pool to the liver. Because avidin causes rapid trapping of the contrast agent in the liver, the blood pool cleared within 2 min of the injection of avidin. This system can be applied to all dendrimer-based macromolecular MRI contrast agents to investigate blood volume and vascular permeability. Moreover, it permits the repeated injection of the contrast agent and the "avidin switch" during a single MR experiment.
引用
收藏
页码：1044 / 1047
页数：4
相关论文
共 24 条
  • [1] Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity
    Chinol, M
    Casalini, P
    Maggiolo, M
    Canevari, S
    Omodeo, ES
    Caliceti, P
    Veronese, FM
    Cremonesi, M
    Chiolerio, F
    Nardone, E
    Siccardi, AG
    Paganelli, G
    [J]. BRITISH JOURNAL OF CANCER, 1998, 78 (02) : 189 - 197
  • [2] Dafni H, 2002, CANCER RES, V62, P6731
  • [3] Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8
  • [4] KOBAYASHI H, 1994, J NUCL MED, V35, P1677
  • [5] Inflammation-seeking scintigraphy with radiolabeled biotinylated polyclonal IgG followed by the injection of avidin chase
    Kobayashi, H
    Sakahara, H
    Endo, K
    Yao, ZS
    Konishi, J
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 1996, 23 (01): : 29 - 32
  • [6] Micro-MR angiography of normal and intratumoral vessels in mice using dedicated intravascular MR contrast agents with high generation of polyamidoamine dendrimer core: Reference to pharmacokinetic properties of dendrimer-based MR contrast agents
    Kobayashi, H
    Kawamoto, S
    Saga, T
    Sato, N
    Hiraga, A
    Konishi, J
    Togashi, K
    Brechbiel, MW
    [J]. JOURNAL OF MAGNETIC RESONANCE IMAGING, 2001, 14 (06) : 705 - 713
  • [7] 3D MR angiography of intratumoral vasculature using a novel macromolecular MR contrast agent
    Kobayashi, H
    Sato, N
    Kawamoto, S
    Saga, T
    Hiraga, A
    Ishimori, T
    Konishi, J
    Togashi, K
    Brechbiel, MW
    [J]. MAGNETIC RESONANCE IN MEDICINE, 2001, 46 (03) : 579 - 585
  • [8] Kobayashi H, 1999, J NUCL MED, V40, P1381
  • [9] Avidin-dendrimer-(1B4M-Gd)254:: A tumor-targeting therapeutic agent for gadolinium neutron capture therapy of intraperitoneal disseminated tumor which can be monitored by MRI
    Kobayashi, H
    Kawamoto, S
    Saga, T
    Sato, N
    Ishimori, T
    Konishi, J
    Ono, K
    Togashi, K
    Brechbiel, MW
    [J]. BIOCONJUGATE CHEMISTRY, 2001, 12 (04) : 587 - 593
  • [10] Kobayashi H, 2001, MAGNET RESON MED, V45, P454, DOI 10.1002/1522-2594(200103)45:3<454::AID-MRM1060>3.0.CO
123